| Insights from global key opinion leaders on optimizing patient care in NSCLC | | |
| Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC | | |
| Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced se… | | |
| Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies | | |
| Guidelines-recommended targeted therapies as second-line treatment options for patients with metast… | | |
| Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies | | |
| Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive me… | | |
| Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC | | |
| Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of … | | |
| Application of guidelines-recommended broad molecular profiling to patients with NSCLC | | |
| Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer | | |
| Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs | 04/10/2025 | |
| Overcoming EGFR Resistance With HER3-Directed ADCs | 04/12/2025 | |
| Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGF… | 04/11/2025 | |
| Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy | 04/11/2025 | |
| Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy | 04/11/2025 | |
| HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI… | | |
| Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting | 04/12/2025 | |
